This scholarly review on the current and future treatment of hidradenitis suppurativa (HS) focuses on medical and surgical treatment options, while novel pipeline drugs are also discussed. Treatment goals are to limit the incidence and duration of flares, reducing inflammation and suppuration, achieving local cure after surgery and, most importantly, to improve the quality of life of patients with HS. The type of medication and/or surgery should be chosen based on the stage of the disease and the degree of inflammation. However, the lack of a simple scoring system and the lack of clear surgical outcome definitions hamper the interpretation of treatment efficacy and the comparison between different treatment strategies. The therapeutic pipeline for HS is gradually expanding, and will probably lead to a broader panel of more effective therapeutic options.

Additional Metadata
Persistent URL dx.doi.org/10.1111/bjd.16768, hdl.handle.net/1765/109590
Journal British Journal of Dermatology
Citation
van Straalen, K.R. (K. R.), Schneider-Burrus, S, & Prens, E.P. (2018). Current and future treatment of hidradenitis suppurativa. British Journal of Dermatology. doi:10.1111/bjd.16768